Preliminary efficacy of TAA targeted therapy in HL has very recently been shown using adoptive T-cell therapy with combined targeting of multiple shared TAAs (PRAME, SSX2, MAGE-A4, SURVIVIN, and NY-ESO-1) by in-vitro expanded T cells [50]. This evidence concerns the gene MAGEA4 and Hodgkins lymphoma.